CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class...
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Strategic Organizational Transition
Cue Biopharma Announces Strategic Organizational Transition
Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri,...
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+...
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Announces Proposed Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Announces Proposed Public Offering
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell...